Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1766 results for patient safety

  1. Contrast-enhanced spectral mammography for breast cancer (MIB304)

    NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .

  2. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  3. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  4. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

  5. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  6. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

    This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

  7. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

  8. Anaphylaxis (QS119)

    This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.

  9. Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)

    NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns

  10. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

  11. Transcranial direct current stimulation (tDCS) for depression (HTG382)

    Evidence-based recommendations on transcranial direct current stimulation (tDCS) for depression. This involves electrical stimulation of the brain by applying a weak direct current to the scalp.

  12. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  13. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  14. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  15. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (HTG689)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.